<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 11, Issue 2</Volume-Issue>
      <Season>April - June, 2019</Season>
      <ArticleTitle>Preparation and characterization of tinidazole-__ampersandsignbeta;-cyclodextrin inclusion complex</ArticleTitle>
      <Abstract>Aim: Preparation and Characterization of Tinidazole-__ampersandsignbeta;-Cyclodextrin Inclusion Complex to increase the aqueous solubility and bioavailability of Tinidazole (TNZ) is an anti-protozoal drug. Method: TNZ was complexed with __ampersandsignbeta;-cyclodextrin (__ampersandsignbeta;-CD) by kneading method in 1:1 molar ratio in order to improve aqueous solubility and bioavailability of TNZ. The complex formation was determined by phase solubility measurements, obtaining AL type of diagram. Prepared complexes were characterized by Fourier transform infrared spectroscopy (FTIR), 1 H - Nuclear Magnetic Resonance (1 H-NMR). Results: The phase solubility diagram of tinidazole with __ampersandsignbeta;-CD in selected concentration range displayed AL type of diagram i.e. solubility of tinidazole was increased with increase in __ampersandsignbeta;-CD concentration under the concentration range that was tested. The in-vitro studies appraised of an increased solubility and dissolution rate of TNZ on complexation with __ampersandsignbeta;-CD as compared to TNZ alone. Conclusion: The complex prepared by kneading method in 1:1 molar ratio demonstrated notable increase in aqueous solubility and dissolution rate.</Abstract>
      <Keywords>Tinidazole, ?-cyclodextrin, Fourier transform infrared, differential  scanning calorimetry, phase solubility, inclusion complex</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13866&amp;title=Preparation and characterization of tinidazole-__ampersandsignbeta;-cyclodextrin inclusion complex</Abstract>
        <References>1. Mangolim CS, Cristiane M, Ana CN, Francielle S, Mauro LB, Antand;ocirc;nio MN, et al. Curcumin-b-cyclodextrin inclusion complex: Stability, solubility, characterisation by FT-IR, FT-raman, X-ray diffraction and photoacoustic spectroscopy, and food application. Food Chem 2014;153:361-70.&#13;
2. Bekers O, Uijtendaal EV, Beijnen JH, Butt A, Underberg WJ. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm 1991;17:1503-9. &#13;
3. Hedges AR. Industrial applications of cyclodextrins. Chem Rev 1998;98:2035-44. &#13;
4. Fromming KH, Szejtli J. Cyclodextrin in Pharmacy. Dordrecht: Kluwer Academic Publishers; 1994. &#13;
5. Lopes MS, Policarpo AS, Amanda GF, Maria IY, Horta AS, Alvaro JR, et al. The activity of a metronidazole analogue and its and;beta;-cyclodextrin complex against Trypanosoma cruzi. Mem Inst Oswaldo Cruz 2011;106:1055-7. &#13;
6. Tally FP, Sutter VL, Flnegold SM. Treatment of anaerobic infections with metronidazole. Antimicrob Agents Chemother 1975;7:672-5.&#13;
7. Goldring J, McNaught W, Scott A, Gillespie G. Prophylactic oral antimicrobial agents in elective colonic surgery. A controlled trial. Lancet 1975;2:997-1000.&#13;
8. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001;14:150-64.&#13;
9. World Health Organization. WHO Model List of Essential Medicines. 16th ed. Geneva: World Health Organization; 2015. Available from: http://www.who. int/medicines/publications/essmedlist15.pdf. [Last accessed on 2019 Jun]. &#13;
10. Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instrum 1965;4:117-212. &#13;
11. Sapkal NP, Kilor VA, Bhusari KP, Daud AS. Evaluation of some methods for preparing gliclazide-and;beta;-cyclodextrin inclusion complexes. Trop J Pharm Res 2007;6:833-40. &#13;
12. Juni E, Retno W, Dewi I. Preparation of an inclusion complex system of ethyl P-methoxycinnamate-hydroxypropyl-and;beta;-cyclodextrin: Characterization and solubility evaluation. Res J Pharm Biol Chem Sci 2017;8:1486-94. &#13;
13. Yapeng LU, Siyuan L, Yu ZL, Shuqin Y. Complexation of Z-ligustilide with hydroxypropyl-and;beta;-cyclodextrin to improve stability and oral bioavailability. Acta Pharm 2014;64:211-22. &#13;
14. Jullian C, Montecinos JM, Torres GZ, Aguilera B, Rodriguez J, Aranc V, et al. Characterization, phase-solubility, and molecular modeling of inclusion complex of 5-nitroindazole derivative with cyclodextrins. Bioorg Med Chem 2008;16:5078-84. &#13;
15. Lee CW, Kim SJ, Youn YS, Widjojokusumo E, Lee YH, Kim J, et al. Preparation of bitter taste masked cetirizine dihydrochloride/and;beta;-cyclodextrin inclusion complex inclusion complex by supercritical antisolvent (SAS) process. J Supercrit Fluids 2010;55:348-57.&#13;
16. Youming Z, Xinrong D, Liangcheng W, Taibao W. Synthesis and characterization of inclusion complexes of aliphatic-aromatic poly (Schiff base) s with and;beta;-cyclodextrin (highlight). J Incl Phenom Macrocycl Chem 2008;60:313-9.&#13;
17. Chen M, Diao G, Zhang E. Study of inclusion complex of and;beta;-cyclodextrin and nitrobenzene. Chemosphere 2006;63:522-9.</References>